Citigroup Inc Nuvalent, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Nuvalent, Inc. stock. As of the latest transaction made, Citigroup Inc holds 94,534 shares of NUVL stock, worth $7.17 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

94,534

Previous 82,278 14.9%

Holding current value

$7.17 Million

Previous $6.24 Million 54.94%

% of portfolio

0.01%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$67.44 - $112.17 $826,544 - $1.37 Million	12,256 Added 14.9%	94,534 $9.67 Million
Q2 2024 Aug 12, 2024	SELL	$62.76 - $81.61 $1.26 Million - $1.64 Million	-20,153 Reduced 19.67%	82,278 $6.24 Million
Q1 2024 May 10, 2024	BUY	$72.35 - $88.99 $2.43 Million - $2.99 Million	33,575 Added 48.76%	102,431 $7.69 Million
Q4 2023 Feb 09, 2024	BUY	$42.42 - $80.28 $1.19 Million - $2.25 Million	28,014 Added 68.59%	68,856 $5.07 Million
Q3 2023 Nov 09, 2023	BUY	$39.12 - $49.85 $385,253 - $490,922	9,848 Added 31.77%	40,842 $1.88 Million
Q2 2023 Aug 10, 2023	SELL	$23.58 - $44.68 $580,940 - $1.1 Million	-24,637 Reduced 44.29%	30,994 $1.31 Million
Q1 2023 May 11, 2023	BUY	$25.42 - $33.52 $853,552 - $1.13 Million	33,578 Added 152.26%	55,631 $1.45 Million
Q4 2022 Feb 09, 2023	BUY	$18.46 - $36.37 $392,681 - $773,662	21,272 Added 2723.69%	22,053 $656,000
Q3 2022 Nov 10, 2022	SELL	$13.55 - $19.92 $15,216 - $22,370	-1,123 Reduced 58.98%	781 $15,000
Q2 2022 Aug 10, 2022	BUY	$7.4 - $15.07 $1,938 - $3,948	262 Added 15.96%	1,904 $26,000
Q1 2022 May 12, 2022	SELL	$11.65 - $19.57 $28,006 - $47,046	-2,404 Reduced 59.42%	1,642 $23,000
Q4 2021 Feb 10, 2022	BUY	$18.01 - $30.1 $50,464 - $84,340	2,802 Added 225.24%	4,046 $77,000
Q3 2021 Nov 10, 2021	BUY	$18.25 - $38.35 $22,703 - $47,707	1,244 New	1,244 $28,000

About Nuvalent, Inc.

Ticker NUVL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,977,800
Market Cap $3.26B
Description
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...

More about NUVL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account